Skip to content

Establishment of risk-reducing salpingo-oohorectomy for hereditary breast and ovarian syndrome

Establishment of risk-reducing salpingo-oohorectomy for hereditary breast and ovarian syndrome - Establishment RRSO for HBOC

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024515
Enrollment
5
Registered
2016-11-01
Start date
2016-10-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer tubal cancer

Interventions

Sponsors

Fujita Health University, Gynecology and Obstetrics
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Female above 20 years old with mutation of BRCA1/2 Female with no ovarian or tuben cancer. Female with prior written consent for operation by voluntary agreement. Female with ECOG PS(Eastern Cooperative Oncology Group Performance Status) 0-2. Female in systemic good condition.

Exclusion criteria

Exclusion criteria: Female with mental disabilities and who has difficulty to make a determination of therapy. Female has active invasive cancer (except for basal cell carcinoma and squamous cell carcinoma and carcinoma in situ). Female during pregnancy and lactation. Femele with following diseases (thrombotic and hemorrhagic disease, uncontrollable hypertension, unstable renal failure, unstable hepatic failure, unhealed wound, unhealed ulcer, and unhealed fracture). Female who a doctor consider inappropriate

Design outcomes

Primary

MeasureTime frame
prognosis(OS, acquiring and recurrence of BRCA related cancer

Secondary

MeasureTime frame
menopausal problem occult cancer QOL of women after RRSO(EORTC QLQ-OV28)

Countries

Japan

Contacts

Public ContactIkue Tanikawa

Fujita Health University Center for Research Promotion and Support

research@fujita-hu.ac.jp0562-93-2865

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026